triple hormone receptor agonist retatrutide for obesity Phase 2 Trial of Retatrutide Severe Obesity Trial Shows

Converting between mcg and mg requires dividing by 1000, so 200mcg equals 0.2mg

When GLP-1 receptors are activated: The hypothalamus receives satiety signals, reducing hunger drive Gastric emptying is slowed, prolonging post-meal fullness Pancreatic beta cells increase insulin secretion in a glucose-dependent manner This is the same pathway targeted by semaglutide and liraglutide

Increased satiety means people eat smaller, less frequent meals

Because it works this way on different metabolic pathways, retatrutide is becoming a strong option in new weight loss medicines

How food supports your natural GLP-1 response No single ingredient is a GLP-1 booster

For patients with thyroid disease, injection-based therapy removes the worry of levothyroxine-GLP-1 timing conflicts